Centrexion Therapeutics is a Biotech company based in Boston. It has raised $108M in total funding. Latest round: Growth.
Centrexion Therapeutics funding overview
Centrexion Therapeutics is a Biotech company based in Boston. Centrexion Therapeutics has raised $108M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Growth announced in October 2020. The round record for Centrexion Therapeutics runs through 2020; nothing later has been disclosed. Investors on record include ELI Lilly And Company, SAM Isaly, Sara Nayeem, Avoro Ventures, David Parkinson, Elliott Sigal and 5 others. 11 distinct backers are named across the disclosed rounds.
Centrexion Therapeutics at a glance
Total raised
$108M
Latest round
Growth
Latest round date
October 2020
Industry
Biotech
Headquarters
Boston
Notable investors
ELI Lilly And Company, SAM Isaly, Sara Nayeem, Avoro Ventures, David Parkinson, Elliott Sigal, 6 Dimensions Capital, ArrowMark Partners
Frequently asked about Centrexion Therapeutics funding
How much has Centrexion Therapeutics raised?
Centrexion Therapeutics has raised $108M in total disclosed funding across the rounds on record.
Who has invested in Centrexion Therapeutics?
ELI Lilly And Company, SAM Isaly, Sara Nayeem, Avoro Ventures, David Parkinson, Elliott Sigal are named among the investors backing Centrexion Therapeutics.
What was the latest Centrexion Therapeutics funding round?
The most recent disclosed round is a Growth, announced in October 2020.
Where is Centrexion Therapeutics based?
Centrexion Therapeutics is based in Boston.
What sector does Centrexion Therapeutics operate in?
Centrexion Therapeutics is tracked under Biotech from Boston, with $108M in disclosed funding.
When did Centrexion Therapeutics last raise?
The last disclosed Centrexion Therapeutics round closed in October 2020 at Growth.
Totals shown for Centrexion Therapeutics aggregate every disclosed round on file. To see how that compares, browse the Biotech companies in Boston and the investors behind them below.
